Hennigsdorf, Germany
Adrenomed AG is a German privately financed, clinical-stage biopharmaceutical company, established in 2009. The company's mission is to rescue vascular integrity to save critically ill patients with limited treatment options. With a focus on sepsis and septic shock, it aims to provide an innovative biomarker-guided precision medicine solution. Adrenomed's lead product candidate, Enibarcimab, is a first-in-class monoclonal antibody targeting the vasoprotective peptide Adrenomedullin. Enibarcimab has undergone a successful biomarker-guided, double-blinded, placebo-controlled, randomized, multicenter proof-of-concept Phase II trial with 301 patients suffering from septic shock.
Founded by a management team with extensive experience in sepsis and deep knowledge in diagnostics and drug development, Adrenomed AG operates in the Biotechnology and Pharmaceutical industries. The last reported investment was a Convertible Note investment on 05 July 2022, with no specific details on the investors provided.
